相关实验视频

Updated: Mar 7, 2026

Protein Engineering by Yeast Surface Display

Protein Engineering by Yeast Surface Display

Published on: November 29, 2024

在体外,腺素A2A受体的演变基于使用核糖体显示器的对手结合

Genki Fukasawa¹, Yuma Matsuoka², Duy Phuoc Tran¹

¹School of Life Science and Technology, Institute of Science Tokyo, Meguro, Tokyo 152 8550, Japan.

Journal of the American Chemical Society

|March 6, 2026

概括

这项研究成功地进化了人体腺A2A受体 (A2AAR) 在体外使用无细胞蛋白质合成和纳米磁盘. 改造后的受体对特定的抗剂表现出增强的敏感性,使得有针对性的信号抑制成为可能.

科学领域:

生物化学生物化学
分子生物学分子生物学
蛋白质工程是指蛋白质工程.

背景情况:

*体外进化对于蛋白质修饰具有强大作用,但对膜蛋白质具有挑战性.
*膜蛋白工程需要一个*体外*的膜环境.

研究的目的:

* 实现人类腺A2A受体 (A2AAR) 的第一个成功的实验室进化.
*为了设计A2AAR,以定制配体结合特性和改进功能.

主要方法:

* 结合无细胞蛋白质合成 (CFPS),用于膜仿真的纳米盘技术和核糖体显示.
* 构建了一个和突变生成库,针对A2AAR残留物L167和L267.
*使用A2AAR选择性对抗剂ZM241385.5进行了三轮亲和力选择.

主要成果:

* 增强的L167N/L267A和L167N/L267S A2AAR突变体. 这些突变体
*在基于细胞的测定中,突变体对ZM241385的敏感性增加了10倍以上.
* 保持对内源性腺的反应,并通过分子动力学证明了通过分子动力学改善的复合稳定性.

结论:

* 开发了一种强大的 * in vitro * 策略来设计G蛋白结合受体 (GPCRs).
*进化的A2AAR突变体在哺乳动物细胞中表现出增强的联结特性和功能.
* 通过使用工程突变体,证明了细胞类型特定的A2AAR信号抑制.

更多相关视频

Genetic and Biochemical Approaches for In Vivo and In Vitro Assessment of Protein Oligomerization: The Ryanodine Receptor Case Study

Genetic and Biochemical Approaches for In Vivo and In Vitro Assessment of Protein Oligomerization: The Ryanodine Receptor Case Study

Published on: July 27, 2016

Directed Evolution Method in Saccharomyces cerevisiae: Mutant Library Creation and Screening

Directed Evolution Method in Saccharomyces cerevisiae: Mutant Library Creation and Screening

Published on: April 1, 2016

相关概念视频

Drug-Receptor Interaction: Antagonist

Drug-Receptor Interaction: Antagonist

An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...